AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

New study introduces a simple blood test to detect early lung damage in cancer patients receiving novel therapy with antibody ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.